MedTrace Logo

Adjuvant Dexmedetomidine and Tramadol in Subcostal Transversus Abdominis Plan Block

NCT05905757 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-06-15

No results posted yet for this study

Summary

In this study, dexmedetomidine and tramadol were added as adjuvant to bupivacaine in transversus abdominis plane block (TAP), intraoperative hemodynamics, opioid consumption, muscle relaxant use, postoperative analgesic effects and side effects (such as nausea-vomiting) were evaluated.

Conditions

  • Transversus Abdominis Plane Block

Interventions

PROCEDURE

Dexmedetomidin + bupivacaine

dexmedetomidine was added as adjuvant to bupivacaine in transversus abdominis plane block (TAP)

DRUG

Tramadol + Bupivacaine

tramadol was added as adjuvant to bupivacaine in transversus abdominis plane block (TAP)

Sponsors & Collaborators

  • Yuzuncu Yıl University

    lead OTHER

Principal Investigators

  • School of Medicine Department of Anesthesiology and Reanimation · Yuzuncu Yıl University

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2023-03-01
Completion
2023-04-03

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05905757 on ClinicalTrials.gov